A few things I gleaned from listening to the Q & A in the CureSHANK webinar this morning:
- The dose used in the trial (which is the same dose that will be used going forward) represents, for a 25kg patient, the equivalent of 5cc (1 teaspoon), taken twice daily.
- While an open label trial design was used in the Phase 2 study, it is expected that Phase 3 will be placebo-controlled.
- Safety was the broad reason for the exclusion of 5 patients after screening.
- Participants in the Phase 3 trial will be excluded from the pivotal Phase 3 trial as neither they nor their parents will be treatment- naïve. However, it is hoped that they can be included in the Phase 3 open label extension component of the trial.
- While not yet decided, it is probable that the pivotal trial will be restricted to the same age group as the Phase 2 trial (3-12 years). However, the company remains committed to extending treatment to all age groups and an additional trial in adolescents is a possibility.
- Geography for the trial is still to be determined.
- The last question was whether it was possible that NNZ-2591 might be applicable to syndromes other than PMS. The founder of CureSHANK was thrilled to hear that NNZ-2591 was being tested in other indications as well and might potentially be a therapeutic used across multiple neurodevelopmental rare diseases.
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Results webinar
Ann: 2023 Results webinar, page-125
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$20.64 |
Change
-0.320(1.53%) |
Mkt cap ! $2.650B |
Open | High | Low | Value | Volume |
$21.00 | $21.21 | $20.31 | $3.182M | 153.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 213 | $20.63 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$20.64 | 117 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 560 | 20.650 |
5 | 180 | 20.640 |
6 | 327 | 20.630 |
6 | 251 | 20.620 |
3 | 225 | 20.610 |
Price($) | Vol. | No. |
---|---|---|
20.670 | 251 | 5 |
20.680 | 332 | 6 |
20.690 | 388 | 5 |
20.700 | 199 | 2 |
20.710 | 199 | 2 |
Last trade - 11.28am 30/05/2024 (20 minute delay) ? |
|
|||||
Last
$20.56 |
  |
Change
-0.320 ( 2.38 %) |
|||
Open | High | Low | Volume | ||
$20.97 | $21.15 | $20.32 | 56197 | ||
Last updated 11.48am 30/05/2024 ? |
Featured News
NEU (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online